Mundipharma Agreement (Tables)

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Schedule of Drug Development Liability Adjustments

We will assess this liability at each subsequent reporting date and record its adjustment through “research and development” expense in our accompanying Condensed Consolidated Statements of Operations.

	Drug Development Liability, Current – FOLOTYN			Drug Development Liability, Long Term – FOLOTYN			Total Drug Development Liability – FOLOTYN
Balance at December 31, 2014	$	1,141		$	14,644		$	15,785
Transfer from long-term to current in 2015	666			(666		)	—
(Less): Expenses incurred in 2015	(666		)	—			(666		)
Balance at March 31, 2015	$	1,141		$	13,978		$	15,119